Vimalanand Shrikant Prabhu

9PUBLICATIONS
12CO-AUTHORS
Epidemiological modellingEpigenetics (incl. genome methylation and epigenomics)Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Preventative health care
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (9)

|Oct 22, 2024
Real-world perioperative treatment patterns and burden of recurrent disease in patients with high-risk endometrial cancer: a SEER-Medicare study.

Vimalanand S Prabhu, Kalé Kponee-Shovein, Mu Cheng

|Jul 13, 2024
Correction: Real-world prevalence of microsatellite instability testing and related status in women with advanced endometrial cancer in Europe.

Sneha S Kelkar, Vimalanand S Prabhu, Jingchuan Zhang

|Apr 18, 2024
Real-world prevalence of microsatellite instability testing and related status in women with advanced endometrial cancer in Europe.

Sneha S Kelkar, Vimalanand S Prabhu, Jingchuan Zhang

|Mar 12, 2024
Cost effectiveness of pembrolizumab plus lenvatinib compared with chemotherapy for treating previously treated advanced endometrial cancer in Sweden.

Lewis Ralph, Kate Young, Navneet Upadhyay

|Oct 13, 2023
Real-world utilization of lenvatinib and pembrolizumab combination therapy for the treatment of endometrial cancer in the USA.

Keiko Wada, Jingchuan Zhang, Inyoung Lee

|Sep 07, 2021
HPV vaccination uptake and administration from 2006 to 2016 in a commercially insured population of the United States.

Vimalanand S Prabhu, Neha Bansal, Zhiwen Liu

Pageof 2

Frequent Collaborators

1 joint publications

Niranjan Kathe

1 joint publications

Evan Myers

1 joint publications

Mark Einstein

1 joint publications

Inyoung Lee